NEW YORK Adams Respiratory Therapeutics, which markets the Mucinex brand, has placed its media planning and buying account at Havas’ MPG without a review, per sources. The incumbent was Interpublic Group’s Initiative.
Ad spending in 2007 exceeded $85 million, up from $65 million the previous year, according to Nielsen Monitor-Plus. Mucinex receives most of the ad backing.
The switch will take effect after a transition period of several months, per sources.
Adams is a specialty pharmaceutical company focused on the development and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in